Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LDLR | P01130 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.36 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.36 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373712 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LDLRGAAFYNCTNNB1 | |
| SCHEMBL5378862 | 0.81 | CTNNB1 (0.52) | ALDH1A1LDLRGAACTNNB1WNT3A | |
| SCHEMBL23428914 | 0.78 | ALDH1A1 (0.49) | ALDH1A1LDLRGAASMN1; SMN2 | |
| SCHEMBL11069056 | 0.72 | L3MBTL1 (0.45) | ALDH1A1GAAPLOD2SMN1; SMN2 | |
| SCHEMBL28836593 | 0.71 | ALDH1A1 (0.51) | ALDH1A1LDLRGAAPLOD2PLOD3 | |
| SCHEMBL18623188 | 0.71 | ALDH1A1 (0.46) | ALDH1A1LDLRGAASMN1; SMN2 | |
| SCHEMBL18604872 | 0.71 | ALDH1A1 (0.46) | ALDH1A1LDLRGAASMN1; SMN2 | |
| SCHEMBL17065074 | 0.70 | ALDH1A1 (0.56) | ALDH1A1LDLRGAACTNNB1WNT3A | |
| SCHEMBL5077141 | 0.69 | THRB (0.56) | ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL14434843 | 0.69 | CYP19A1 (0.49) | ALDH1A1GAAPLOD2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185086-A1 | Pharmaceutical Compositions and Methods for Effecting Dopamine Release | BENCHERIF MEROUANE | 2007-08-09 | — | — | US | disclosed |
| US-7214686-B2 | Pharmaceutical compositions and methods for effecting dopamine release | TARGACEPT, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20040220214-A1 | Pharmaceutical compositions and methods for effecting dopamine release | TARGACEPT, INC. | 2004-11-04 | — | — | US | disclosed |
| EP-0994875-B1 | 3-PYRIDYL-1-AZABICYCLOALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | TARGACEPT INC (US) | 2004-03-10 | — | — | EP | disclosed |
| US-6624173-B1 | Characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) treated by | TARGACEPT, INC. | 2003-09-23 | — | — | US | disclosed |
| US-6525065-B1 | Central nervous system disorders; administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo(2.2.1)heptane, or a 1-aza-7-(3-pyridyl)bicyclo(3.2.2) nonane, or a 1-aza-2-(3-pyridyl)bicyclo(2.2.2)octane | TARGACEPT, INC. | 2003-02-25 | — | — | US | disclosed |
| EP-0994875-A1 | 3-PYRIDYL-1-AZA-BICYCLO-ALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999000385-A1 | 3-PYRIDYL-1-AZA-BICYCLO-ALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220214-A1 | Pharmaceutical compositions and methods for effecting dopamine release | COMT, SLC6A3, PARK7 | ALDH1A1 1466/4885LDLR 1991/4885GAA 322/4885 |
| US-20070185086-A1 | Pharmaceutical Compositions and Methods for Effecting Dopamine Release | COMT, SLC6A3, HTR2A | ALDH1A1 1069/4885LDLR 1584/4885GAA 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.